Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Top Diwali Stock Picks for 2024-2025, Diwali Picks for Samvat 2081

By Jagat Joshi
November 1, 2024

Which stocks to buy in Diwali muhurat trading 2024? Here are the top Diwali stock picks for 2024-2025 in Diwali muhurat trading today. The BSE and NSE will conduct a special 1-hour "Muhurat Trading Session" today to start a new year of Samvat 2081.

Diwali Muhurat Trading Timing 2024

Session Type	Muhurat Trading Timing
Block Deal Session	5:30 pm to 5:45 pm
Pre-Open Session	5:45 pm to 6:00 pm
Muhurat Trading Session	6:00 pm to 7:00 pm
Call Auction Session	6:05 pm to 6:50 pm
Closing Session	7:10 pm to 7:20 pm
Muhurat Trading Duration	1 Hour

In today’s Diwali Muhurat Trading Session, the market will open in the evening starting at 6:00 PM to 7:00 PM. The market will remain closed in the morning to conduct an auspicious trading session in the Indian stock market today. Let’s talk about the Diwali Stock Picks of 2024-2025 recommended by the top stock brokers and brokerage houses in India.

Diwali Stock Picks by JM Financial for Muhurat Trading

ICICI Bank Share Price Target 2025
Current Price: ₹1418
Target Price: ₹1410 and ₹1545

Infosys Share Price Target 2025
Current Price: ₹1841
Target Price: ₹2025 to ₹2200

Tata Power Share Price Target 2025
Current Price: ₹419
Target Price: ₹500 to ₹550

Bajaj Finserv Share Price Target 2025
Current Price: ₹1771
Target Price: ₹1940 to ₹2200

Lupin Share Price Target 2025
Current Price: ₹2196
Target Price: ₹2445 to ₹2750

ONGC Share Price Target 2025
Current Price: ₹263
Target Price: ₹315 to ₹365

HDFC Life Share Price Target 2025
Current Price: ₹742
Target Price: ₹850 to ₹950

Tata Chemical Share Price Target 2025
Current Price: ₹1091
Target Price: ₹1340 to ₹1525

NALCO Share Price Target 2025
Current Price: ₹223
Target Price: ₹265 to ₹305

Dixon Tech Share Price Target 2025
Current Price: ₹14949
Target Price: ₹18250 to ₹20500

Diwali Stock Picks by 5Paisa for Muhurat Trading

Reliance Industries Share Price Target 2025
Current Price: ₹1332
Target Price: ₹1515 to ₹1625

State Bank of India (SBI) Share Price Target 2025
Current Price: ₹821
Target Price: ₹915 to ₹970

Bharat Dynamics Share Price Target 2025
Current Price: ₹1085
Target Price: ₹1190 to ₹1300

Olectra Greentech Share Price Target 2025
Current Price: ₹1643
Target Price: ₹1860 to ₹2040

Mphasis Share Price Target 2025
Current Price: ₹2883
Target Price: ₹3560 to ₹3880

Diwali Stock Picks by Religare for Muhurat Trading

BEL Share Price Target 2025
Current Price: ₹283
Target Price: ₹308 to ₹330

CUB Share Price Target 2025
Current Price: ₹175
Target Price: ₹194 to ₹204

Federal Bank Share Price Target 2025
Current Price: ₹204
Target Price: ₹218 to ₹226

Fortis Share Price Target 2025
Current Price: ₹625
Target Price: ₹665 to ₹680

GMDC Share Price Target 2025
Current Price: ₹370
Target Price: ₹368 to ₹372

Diwali Stock Picks by Bajaj Broking for Muhurat Trading

Tech Mahindra Share Price Target 2025
Buying Range Price: ₹1680-1730
Target Price: ₹2120

Bharat Electronics (BEL) Share Price Target 2025
Buying Range Price: ₹264-274
Target Price: ₹335

CESC Share Price Target 2025
Buying Range Price: ₹180-190
Target Price: ₹245

Antony Waste Handling Share Price Target 2025
Buying Range Price: ₹700-745
Target Price: ₹990

Agro Tech Food Share Price Target 2025
Buying Range Price: ₹910-920
Target Price: ₹1230

Diwali Stock Picks by Prabhudas Lilladher Capital for Muhurat Trading

Coal India Share Price Target 2025
Target Price: ₹690

Tech Mahindra Share Price Target 2025
Target Price: ₹2120

GMDC Share Price Target 2025
Target Price: ₹544

NTPC Share Price Target 2025
Target Price: ₹590

Tata Motors Share Price Target 2025
Target Price: ₹1225

Diwali Stock Picks by Prabhudas Lilladher Capital for Muhurat Trading

PNB Housing Finance Share Price Target 2025
Target Price: ₹1333

Shriram Properties Share Price Target 2025
Target Price: ₹152

Jana Small Finance Bank Share Price Target 2025
Target Price: ₹700

One97 Communications (Paytm) Share Price Target 2025
Target Price: ₹900

Protean eGov Technologies Share Price Target 2025
Target Price: ₹2459

GMR Airports Infrastructure Share Price Target 2025
Target Price: ₹108

Lemon Tree Hotels Share Price Target 2025
Target Price: ₹155

NALCO Share Price Target 2025
Target Price: ₹275

Zomato Share Price Target 2025
Target Price: ₹320

Jash Engineering Share Price Target 2025
Target Price: ₹3000

Note for the investors:
All the above information provided is for education purposes only. We do not claim any facts, and figures mentioned above. If anyone has any queries kindly contact us on our email ipowatchinfo@gmail.com.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.